Symbol="ASLN"
AssetType="Common Stock"
Name="Aslan Pharmaceuticals Ltd ADR"
Description="ASLAN Pharmaceuticals Limited, a biopharmaceutical company focused on clinical phase immunology, is dedicated to developing various treatments to transform the lives of patients. The company is headquartered in Singapore."
CIK="1722926"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="83 CLEMENCEAU AVENUE, #12-03 UE SQUARE, SINGAPORE, SG"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="44709600"
EBITDA="-54072000"
PERatio="None"
PEGRatio="None"
BookValue="0.667"
DividendPerShare="0"
DividendYield="0"
EPS="-4"
RevenuePerShareTTM="0.005"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.447"
ReturnOnEquityTTM="-2.094"
RevenueTTM="189710"
GrossProfitTTM="79821000"
DilutedEPSTTM="-4"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="15.67"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="19.05"
PriceToBookRatio="1.584"
EVToRevenue="16.94"
EVToEBITDA="-0.062"
Beta="1.797"
num_52WeekHigh="4.945"
num_52WeekLow="1.702"
num_50DayMovingAverage="3.685"
num_200DayMovingAverage="3.193"
SharesOutstanding="16347200"
DividendDate="None"
ExDividendDate="None"
symbol="ASLN"
open="2.80"
high="2.80"
low="2.69"
price="2.73"
volume="18785.00"
latest_trading_day="2023-07-21"
previous_close="2.81"
change="-0.07"
change_percent="-2.6690%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="34"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="66"
Volume_recent_avg="125526"
Change_recent_avg="0.01"
Delta_recent_avg="0.27"
Variance_recent_avg="0.13"
Change_ratio_recent_avg="-0.22"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="66"
Aroon_momentum_negative="34"
image_negative_thumbnail_id_1="1152"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0185.jpeg"
image_negative_thumbnail_id_2="1145"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0178.jpeg"
image_neutral_thumbnail_id_1="579"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0020.jpeg"
image_neutral_thumbnail_id_2="549"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0050.jpeg"
image_positive_thumbnail_id_1="631"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0077.jpeg"
image_positive_thumbnail_id_2="663"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0045.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1198"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
